Download Prostate Cancer Studies

Prostate Cancer Studies
Cougar 301 - Zytiga™
Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate
cancer who have already received chemotherapy Closed to enrollment
Cougar 302 - Zytiga™
Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate
cancer who have not yet received treatment with chemotherapy Closed to
enrollment
Rising PSA - Taxotere® added to Eligard®
Phase III study of Taxotere® added to Eligard® as curative for patients with rising PSA
prostate cancer Closed to enrollment
Extended Access - Zytiga™
Open label study of oral Zytiga™ plus prednisone for patients with advanced prostate
cancer who have already received chemotherapy Closed to enrollment
Rising PSA - Zytiga™
Phase III study of oral Zytiga™ plus prednisone for patients with rising PSA prostate
cancer who are receiving hormone therapy Recruiting
PROCEED - Provenge®
Registry study to collect long term safety data for patients receiving Provenge ® vaccine
Recruiting
TAK-700 (Orteronel)
Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer
who have not yet received treatment with chemotherapy Recruiting
Study information link: http://elmpctrials.com/
TAK-700 (Orteronel)
Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer
previously treated with chemotherapy Recruiting
Study information link: http://elmpctrials.com/
Taxotere®
Phase III study to evaluate the addition of Taxotere® prior to surgery to improve
outcome for patients with newly diagnosed high risk prostate cancer Recruiting
TroVax®
Phase II study to evaluate the addition of TroVax® vaccination to standard Taxotere®
chemotherapy for patients with advanced prostate cancer Recruiting
Prostvac®
Phase III study vaccination study for patients with advanced prostate cancer who have
not yet received treatment with chemotherapy and have no symptoms or minimal
symptoms Recruiting
Prolia®
Phase III study to evaluate Prolia® for patients with prostate cancer taking hormones.
Recruiting
TAK-700 (Orteronel)
Phase II open-label study of oral TAK-700 plus prednisone for patients with advanced
prostate cancer Study pending
VT-464-CL-001 (testosterone inhibitor)
Phase 1/2 study to evaluate the safety of the study drug VT-464(pill) and how it affects
patients with prostate cancer. This is the first time the treatment has been tested in
people Study pending
Zytiga™+/- Genentec GDC
Phase II study of GDC + Zytiga™, versus Zytiga™ alone for patients with advanced
prostate cancer previously treated with chemotherapy Study pending
MDV3100
Study of MDV3100 in prostate cancer patients with rising PSA Study pending
Exelixis Cabozantinib
Phase III study of cabozantinib for patients with advanced prostate cancer Study
pending
Oncogenex Custirsen
Phase III study of Custirsen added to Jevtana® in patients with advanced prostate
cancer Study pending
Bladder Cancer Studies
Gemcitabine, Cisplatin, and Avastin chemotherapy
A Phase II study comparing IV chemotherapy treatments Gemcitabine, Cisplatin,
(Gem/Cis) and Avastin to Gemcitabine, Cisplatin only in advanced bladder cancer
Recruiting
OGX-427-02 added to Gemcitabine + Cisplatin chemotherapy
Phase II study of Gemcitabine + Cisplatin chemotherapy with study drug OGX-427-02
for advanced bladder cancer Recruiting
Intravesical chemotherapy with
Gemcitabine/Mitomycin/Taxotere®
Treatment for superficial bladder cancer in which chemotherapy drugs are infused
directly into the bladder through a catheter (intravesical) Recruiting
Bladder preservation
Bladder preservation with chemotherapy prior to surgery, TURBT (transurethral
resection of bladder tumor), concurrent radiation + chemotherapy Recruiting
Kidney Cancer Studies
AVE0005 (veg trap)
Phase II study to determine the effects of two different doses of AVE0005 (veg trap) in
patients with advanced kidney cancer
Sutent®
Treatment with Sutent® (pill) prior to surgery/cryosurgery